Nestlé in society Creating Shared Value and meeting our commitments 2015

Nestlé in society:
Creating Shared Value
Nutrition, health
and wellness
Rural development
Water
Environmental
sustainability
Human rights
and compliance
Our
people
Novel Therapeutic Nutrition
We invested in Seres Therapeutics, a leader in developing a
new class of biological drugs designed to treat diseases by
restoring gut function. One development that our investment
supports is phase III trials of SER-109, for the prevention of
recurrent Clostridium difficile infection (CDI) in adults – a
condition that affects 85 000 to 110 000 patients in the United
States alone and is caused by antibiotic disruption of the gut
microbiome. The FDA designated SER-109 an orphan drug and
a breakthrough therapy in 2015.
In January 2016, Nestlé Health Science signed an exclusive
agreement outside the United States and Canada for Seres
Therapeutics’ novel class of microbiome therapeutics
(Ecobiotics®) in the fields of Clostridium difficile infections (CDI,
such as SER-109 and SER-262) and inflammatory bowel disease
(IBD; such as SER-287 and SER-301). The agreement follows
Nestlé Health Science’s initial equity investments in US-based
Seres Therapeutics announced in January and July 2015.
• Nutrition Science Partners, a joint venture exploring the
potential of botanical-based nutrients for gastrointestinal
disorders;
• Accera, which supports nutritional therapy trials for
Alzheimer’s sufferers (in which Nestlé has a minority stake);
• Seres Therapeutics, developing microbiome therapeutics
focused on IBD and C. diff (a GI infectious disease) – are all
interacting with the gut microbiota;
• Lipid Therapeutics, developing a novel barrier function
therapy for patients with mild-to-moderate ulcerative colitis;
and
• Pronutria Biosciences (announced on 23 February 2016),
developing amino acid biologics, Pronutreins TM , targeting
irregularities in amino acids, increasingly known to have
underlying associations with a range of conditions.
Nestlé Skin Health
Supporting new therapies
More than 1 million people worldwide are estimated to suffer
from ulcerative colitis, a chronic and debilitating inflammatory
condition of the large intestine. It is estimated that 40% of
patients that receive the most common treatment, Mesalazine,
still suffer ongoing symptoms of the disease.
NHSc has entered into a licence agreement with Lipid
Therapeutics for exclusive rights worldwide (except for Europe
and Australia) to LT-02, a novel barrier function therapy for
patients with mild-to-moderate ulcerative colitis. LT-02 can not
only help heal ulcers but also restore the lining of the colon wall,
preventing further occurrences. NHSc plans to start phase III
clinical trials in the United States in 2016. We hope to advance
patient outcomes for those who suffer from ulcerative colitis.
Through investment, innovation and geographic expansion,
we are accelerating the growth and development of our
established Consumer Care and Medical Nutrition business
areas. Both are operating in growing markets driven by mega
trends – ageing population, cost pressure, self-care, scientific
and clinical advances and geographic development. We are
gearing to bring forward breakthrough innovations in Novel
Therapeutic Nutrition – building a portfolio of clinically proven
nutritionally based innovations with a more direct therapeutic
impact and known mode of action. We aim to address unmet
needs. Since its creation, NHSc has made acquisitions and
forged a number of partnerships since 2011. These include:
• Vitaflo, specialists in treating genetically inherited
metabolic disorders;
• Prometheus Laboratories, a provider of diagnostics
and pharmaceuticals in gastroenterology and oncology;
• Pamlab, a producer of medical foods for brain and
metabolic disorders;
Through Nestlé Skin Health, we enhance the quality of life by
delivering science-based solutions for the health of skin, hair and
nails over the course of people’s lives.
An estimated 3000 skin diseases are known to exist, more than
for any other organ of the body, and approximately 70% of people
are affected by these conditions at some point in (if not for all of)
their lives. Our innovative products and solutions are designed to
protect, nourish and enhance, as well as treat, correct and restore.
Nestlé Skin Health was founded in June 2014, growing out of
Galderma, a leading dermatology company dating back to 1961. It
employs approximately 6000 people worldwide. Nestlé Skin
Health provides both the healthcare community and the
consumer with an ongoing progression of innovative technologies
and products to protect, serve and enhance skin health. It
achieves this through Galderma, its medical solutions business,
and Consumer Skin Health, through which it aims to bring
science-based innovation to the broader market.
Much of Nestlé Skin Health’s work depends on product
research and development, and our dedicated Skin Health
R&D division employs more than 700 people for the purpose.
Since the company’s inception, more than 2000 scientific
publications have been issued and more than 6000 patent
applications have been filed. In 2015, we filed 57 new
applications and conducted more than 200 clinical studies
involving subjects from around the world.
Expanding borders: skin health and ageing
Advances in healthcare and technology are resulting in longer
lives. As people live longer, their needs and expectations change.
We want to help people keep healthy skin as they age. Nestlé Skin
Health works closely with academia and institutions to find
improved methods for preserving, restoring and maintaining
healthy skin. By partnering with healthcare professionals and
institutions around the world, we strive to build and sustain a
strong and long-lasting dermatology community.
Nestlé in society – Creating Shared Value and meeting our commitments 2015 58